Brief Article
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Diabetes. Oct 15, 2013; 4(5): 210-218
Published online Oct 15, 2013. doi: 10.4239/wjd.v4.i5.210
Impaired fasting glucose: Pro-diabetic, “atheroprotective” and modified by metabolic syndrome
Altan Onat, Mesut Aydın, Günay Can, H Altuğ Çakmak, Bayram Köroğlu, Ayşem Kaya, Evin Ademoğlu
Altan Onat, Turkish Society of Cardiology, and Emeritus, Department of Cardiology, Cerrahpaşa Medical Faculty, Istanbul University, 34335 Etiler, Turkey
Mesut Aydın, Department of Cardiology, Dicle University Medical Faculty, 21200 Diyarbakır, Turkey
Günay Can, Department of Public Health, Cerrahpaşa Medical Faculty, Istanbul University, 34099 Istanbul, Turkey
H Altuğ Çakmak, Department of Cardiology, Cerrahpaşa Medical Faculty, Istanbul University, 34099 Istanbul, Turkey
Bayram Köroğlu, Siyami Ersek Center for Cardiovascular Surgery, Research and Training Hospital, 34668 Istanbul, Turkey
Ayşem Kaya, Section of Biochemistry, Cardiology Institute, Istanbul University, 34096 İstanbul, Turkey
Evin Ademoğlu, Department of Biochemistry, Istanbul Medical Faculty, Istanbul University, 34093 İstanbul, Turkey
Author contributions: Onat A designed the study and wrote manuscript; Aydın M, Çakmak HA and Köroğlu B collected data, revised critically for intellectual content and approved the final version; Can G provided data analyses and approved the final version; Kaya A and Ademoğlu E performed biochemical analyses and approved the final version.
Supported by The Turkish Society of Cardiology
Correspondence to: Dr. Altan Onat, Professor, Turkish Society of Cardiology, and Emeritus, Department of Cardiology, Cerrahpaşa Medical Faculty, Istanbul University, Nisbetiye cad. 59/24, 34335 Etiler, Istanbul, Turkey. alt_onat@yahoo.com.tr
Telephone: +90-212-3516217 Fax: +90-212-2211754
Received: January 16, 2013
Revised: March 24, 2013
Accepted: August 12, 2013
Published online: October 15, 2013
Processing time: 272 Days and 16.8 Hours
Core Tip

Core tip: The study investigated whether and to what extent impaired fasting glucose (IFG) conferred risk of type 2 diabetes or coronary heart disease in 3181 middle-aged adults, by separately stratifying to gender and metabolic syndrome. Follow-up over 8.5 years revealed both factors to modulate future risk. In women without metabolic syndrome, IFG was not associated with either cardiometabolic disorder, while in men, IFG imparted risk of diabetes alone. Coronary heart disease risk appeared to depend on the core components of the metabolic syndrome, especially in the female. The results implicate autoimmune activation involving lipoprotein(a) to be of high relevance in the pathogenesis of new-onset diabetes.